Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics

Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia... Key PointsQuestionMeta-analyzing nonrandomized cohort studies, how does clozapine compare with other second-generation antipsychotics (SGAs)? FindingsIn this systematic review and meta-analysis of 63 cohort studies comprising 109 341 participants, although more severely ill patients received clozapine, use of clozapine was associated with better effectiveness outcomes regarding hospitalization, all-cause discontinuation, and overall symptoms but with a higher risk of cardiometabolic-related outcomes vs other SGAs. MeaningIn a more generalizable sample of patients with schizophrenia than in randomized trials, clozapine was statistically and clinically associated with better effectiveness outcomes compared with other SGAs, but some concerns about safety require careful monitoring and clinical attention. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics

Loading next page...
 
/lp/american-medical-association/association-with-hospitalization-and-all-cause-discontinuation-among-McW5bTyig0
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2019.1702
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionMeta-analyzing nonrandomized cohort studies, how does clozapine compare with other second-generation antipsychotics (SGAs)? FindingsIn this systematic review and meta-analysis of 63 cohort studies comprising 109 341 participants, although more severely ill patients received clozapine, use of clozapine was associated with better effectiveness outcomes regarding hospitalization, all-cause discontinuation, and overall symptoms but with a higher risk of cardiometabolic-related outcomes vs other SGAs. MeaningIn a more generalizable sample of patients with schizophrenia than in randomized trials, clozapine was statistically and clinically associated with better effectiveness outcomes compared with other SGAs, but some concerns about safety require careful monitoring and clinical attention.

Journal

JAMA PsychiatryAmerican Medical Association

Published: Oct 31, 2019

References